Toripalimab consolidation after chemoradiotherapy in limited-stage small cell lung cancer: a phase II, randomized controlled study (GASTO-1052A).
Consolidative immunotherapy after standard treatment showed improved survival signals in early-stage small cell lung cancer with manageable side effects.
This randomized controlled trial examined Toripalimab consolidation after chemoradiotherapy in limited-stage small cell lung cancer: a phase II, randomized controlled study (GASTO-1052A). Consolidative toripalimab showed promising signals of improved PFS and OS with a manageable safety profile in patients with LS-SCLC.
What the study was
- Study design
- Randomized controlled trial
- Population
- Human participants or patients described in the PubMed abstract
- Sample size
- 49
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Journal for immunotherapy of cancer
Why it surfaced
Randomized controlled trial; conservative rapid-triage score based on novelty, clinical relevance, design quality, and population or unmet need.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.